Positive Final WSU Trial Results To Support IND Submission
Filed with ASX · · 3 pages · English
Ø Compelling results from the Wayne State collaboration strongly support the scientific rationale for the MagSense® Phase 2 trial design for HER2 breast cancer patients Ø Strategic trial partners now in place, preparing for commencement of the Phase 2 clinical trial in early 2026 Imagion Biosystems (ASX: IBX) (Company or Imagion), is dedicated to improving healthcare outcomes through the early det
Imagion Biosystems Ltd. on 6ix
Earlier from Imagion Biosystems
- Positive Results Received from WSU on MagSense Dosage
- Appendix 4C and Quarterly Activities Report - September 2025
- Imagion Biosystems HER2 Breast Cancer Program Update
- Ph2 Manufacturing & Imaging Optimisation Activities Commence
- Appendix 4D and Half-yearly Financial Report
Later from Imagion Biosystems
- Mercer Convertible Securities Conversion and Amendment
- Appendix 4C and Quarterly Activities Report - December 2025
- IBX's IND Application Lodged with FDA for HER2 Phase 2 Trial
- Medical-imaging company Imagion Biosystems Lodges IND with FDA for Phase 2 Trial of MagSense® HER2 targeted imaging agent
- FY25 Appendix 4E and Annual Report
Follow Imagion Biosystems into a list and get an email when it puts out news.
Follow Imagion Biosystems